Aurora Cannabis Inc. Stock News

EDMONTON, Alberta--(BUSINESS WIRE)--Aurora Cannabis Inc. (the “Company” or “Aurora”) (NASDAQ | TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2027 ending September 30, 2026. Aurora has cancelled its investor call, originally scheduled for November 12, 2026, at 8:00 a.m. Eastern Time | 6:00 a.m. Moun...

STAMFORD, Conn., Nov. 3, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading international provider of consumer and medical cannabis products, today acknowledges the announcement by Aurora Cannabis Inc. (TSX: ACB) (NASDAQ: ACB) ("Aurora") of an alternative transaction from Organigram Global Inc. ("Organigram").

TORONTO & EDMONTON, Alberta--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (“Organigram”) and Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) (“Aurora”) today announced that they have entered into an arrangement agreement (the “Arrangement Agreement”) pursuant to which Organigram will acquire all of the issued and outstanding common shares (the “Aurora Shares”) of Aurora at a p...

NASDAQ | TSX: ACB Alberta Securities Commission dismisses Curaleaf's application concerning Aurora's ATM program. Curaleaf's unsuccessful application before the Alberta Securities Commission confirms Aurora's ATM program is compliant with Securities laws.

NASDAQ | TSX: ACB Revised Hostile Bid continues to significantly undervalue Aurora; fails to address concerns previously raised by the Board.  Aurora's Special Committee is actively exploring strategic alternatives to maximize value for Aurora shareholders.

NASDAQ | TSX: ACB Multi-million-dollar investment results in increased domestic production capacity in Germany, more than doubling expected annual flower output. Enhanced facility adopts Aurora's proven cultivation practices and proprietary genetics to support consistent, high-quality production.

Aurora's Special Committee will commence a thorough and independent review of the revised Hostile Bid and the Board will provide a formal recommendation to shareholders once the review is complete.   Shareholders are advised to TAKE NO ACTION pending a formal recommendation.

NASDAQ | TSX: ACB Curaleaf has yet to file a Notice of Variation and Change to revise its offer. Once filed, the Special Committee will complete a thorough and comprehensive review prior to issuing a formal recommendation to shareholders Aurora's application to the Alberta Securities Commission delivered results for shareholders: Curaleaf's latest update indicates that Aurora shareholders will ...